Recent Finacing
Recent Raise
ClostraBio develops next-generation lower-gut therapeutics—human-derived CLB101 probiotic for continuous butyrate production—and a polymeric prodrug platform, operating from Chicago and launching CLB101-based supplements with U.S. practitioner partners in 2025.
